JSPR - Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc.
2200 Bridge Pkwy
Suite 102
Redwood City, CA 94065
United States
650 549 1400
https://www.jaspertherapeutics.com/
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 35
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Ronald A. Martell | Pres, CEO & Director | 892.45k | N/A | 1962 |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Chair of Scientific Advisory Board & Director | 291.25k | N/A | 1957 |
| Mr. Jeetinder Singh Mahal M.B.A. | CFO, COO & Corp. Sec. | 579.46k | N/A | 1973 |
| Dr. Luca Di Noto Ph.D. | Sr. VP of Technical Operations | N/A | N/A | N/A |
| Mr. David Ku M.D. | VP of Corp. Devel., Portfolio Strategy & Management | N/A | N/A | N/A |
| Mr. Matthew Ford | VP of HR | N/A | N/A | N/A |
| Dr. Wendy Pang M.D., Ph.D. | Sr. VP of Research & Translational Medicine | N/A | N/A | N/A |
| Dr. Daniel C. Adelman M.D. | Acting Chief Medical Officer | N/A | N/A | 1957 |
| Mr. David Hinds | Sr. VP of Devel. Operations | N/A | N/A | N/A |
| Mr. Arjun Agarwal CPA | VP of Fin. & Corp. Controller | N/A | N/A | N/A |
Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
Corporate governance
Jasper Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
